These trials confirmed clinically substantial pharmacokinetic interactions [7] characterised by a reduce during the clearance on the anticancer drug and therefore amplified exposure. The interpretation of subsequent section II and III scientific trials was intricate since it was not possible to administer the identical dose of chemotherapy while in